Chromatin binding alteration after enzalutamide treatment

In this study, we found the efficacy of AR-targeting drugs largely depended on the context of AR (Androgen Receptor) and ERa (Estrogen Receptor) status. Enzalutamide, an AR blocker, had a better inhibition effect on ER+ cells with lower AR expressed compared to cells expressed higher AR. To explore the mechanism of action of Enzalutamide, we performed ChIP-seq to illustrate the AR and ER genomic bindings after Enzalutamide treatment in both MCF7 and MCF7 with AR over expression (AROE) cells. Chromatin immunoprecipitation DNA-sequencing (ChIP-seq) for androgen receptor (AR) and Estrogen receptor (ER) after Enzalutamide treatment in MCF7 and MCF7 AROE cells Overall design: AR and ER ChIP-seq were performed under four conditions, DMSO treatment in parental MCF7 cells, Enzalutamide treatment in parental MCF7 cells, DMSO treatment in AROE MCF7 cells and Enzalutamide treatment in AROE MCF7 cells.